AbbVie IncNYSE: ABBV
Health Care · Biotechnology
$221.50
-0.44%
Vol: 2.6M
Research Digest
Wednesday, June 17, 2026
No significant overnight updates
No material news in the last 48 hours.
Previous Market Intelligence
13 daysJun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14AbbVie showcases broad blood-cancer data at EHA 2026 and wins expanded EU VENCLYXTO label, though Citi stays on the sidelinesPositive▶
AbbVie presented extensive new data across its hematology portfolio at the European Hematology Association (EHA) 2026 Congress on June 12, including 21 oral and poster presentations on epcoritamab, venetoclax, etentamig (ABBV-383) and pivekimab sunirine, plus long-term venetoclax benefit data in chronic lymphocytic leukemia. The European Commission authorized an expanded label for VENCLYXTO (venetoclax) in CLL, and AbbVie recently secured FDA approval for DECNUPAZ in BPDCN and a positive CHMP opinion for MAVIRET. Citi assigned a Hold rating on June 12, 2026, signaling a cautious near-term view. AbbVie projects next-quarter EPS of $3.79 on revenue of ~$16.8B. The risk is competitive pressure, with UCB's Bimzelx outperforming Skyrizi in psoriatic arthritis studies, threatening a key growth driver.
May 21AbbVie shares rose 2.13% to $213.86 on May 19 as raised FY26 guidance and Skyrizi/Rinvoq growth continue driving immunology momentum.Positive▶
AbbVie gained 2.13% on May 19 to $213.86 as the Q1 2026 immunology growth narrative continued (Skyrizi +30.9% YoY, Rinvoq +23.3% YoY). Management raised full-year guidance to $67.3B in revenue (10% growth) and adjusted EPS of $14.08-$14.28 (40-42% growth). The company submitted SKYRIZI for subcutaneous induction in Crohn's disease (FDA filing announced April 27). AbbVie presented 18 abstracts at Digestive Disease Week (May 2-5) and participated in BofA Securities Healthcare Conference May 13. Analyst consensus remains Buy with average PT of $255.06 (~21% upside).
May 20AbbVie shares hold near $209 as Piper Sandler and Evercore ISI raise price targets on Skyrizi/Rinvoq momentumPositive▶
AbbVie traded at $209.41 on May 18 after Piper Sandler raised its target to $298 from $294 and Evercore ISI lifted to $236 from $232 following continued strength in immunology. Skyrizi revenue grew 30.9% YoY and Rinvoq 23.3% YoY in Q1 2026, supporting the raised full-year adjusted EPS guidance of $14.08-$14.28 (from $13.96-$14.16). On May 13, AbbVie presented at BofA Securities Healthcare Conference; on May 5 it showcased 18 IBD abstracts at Digestive Disease Week. Pipeline progress includes the ABBV-295 obesity trial expansion. Risk: Humira biosimilar erosion and pipeline execution; shareholders rejected supermajority voting and independent chair proposals.
May 19AbbVie ABBV-951 Parkinson's extension study completes May 14, setting up long-term safety readout while analysts hike PTsPositive▶
AbbVie disclosed completion of the ABBV-951 Parkinson's disease extension study on May 14, 2026, setting up a key long-term safety and durability readout that bolsters the neuroscience pipeline. Recent analyst PT hikes include BofA upgrading ABBV to Buy from Neutral with a $234 PT (up from $226), Morgan Stanley raising to $278 from $270 (Overweight), and Piper Sandler to $298 from $294 (Overweight). The setup follows AbbVie's Q1 earnings beat driven by SKYRIZI/RINVOQ immunology momentum, an announced $1.4B Durham, NC manufacturing campus with 734 hires, and 18 abstracts presented at Digestive Disease Week. Average 32-analyst PT is $252.90 (Buy, 20.8% upside). Risk: Humira biosimilar erosion continues to weigh on top-line and shares are down ~9% YTD.
May 18AbbVie's Parkinson's drug ABBV-951 extension study completed setting up a key long-term safety readout, and Piper Sandler lifted its price target to $298 from $294.Positive▶
AbbVie announced that its ABBV-951 Parkinson's disease extension study has completed, setting up a key long-term safety readout for one of the company's important neuroscience programs. The pipeline catalyst follows extensive new real-world and long-term data presented for immunology blockbusters SKYRIZI and RINVOQ at Digestive Disease Week (May 2-5), reinforcing leadership in IBD. Piper Sandler raised its target to $298 from $294 (Overweight) on the back of upgraded earnings outlook. Shares traded between $209 and $215 on May 18. The main risk remains Humira's ongoing erosion and competition in immunology, though SKYRIZI/RINVOQ growth has more than offset losses to date.
May 15AbbVie expands obesity bet with new Phase 1b ABBV-295 trial and Evercore lifts PT to $236 ahead of additional DDW gastro data presentationsPositive▶
AbbVie announced a new Phase 1b study for ABBV-295, a subcutaneous obesity drug, marking a meaningful push into the GLP-1/weight-loss market. On May 4, Evercore ISI raised its price target to $236 from $232 (Outperform). On May 5, the company presented new gastroenterology data for SKYRIZI and RINVOQ at the 2026 Digestive Disease Week meeting, supporting durability claims in Crohn's and ulcerative colitis. Recent FDA submissions include SKYRIZI for subcutaneous induction in Crohn's (Apr 27) and RINVOQ for severe alopecia areata. Q1 2026 revenue was $15.0B (+12.4% YoY) with adjusted EPS of $2.65, beating consensus; Skyrizi grew 30.9% YoY and Rinvoq 23.3%. BofA upgraded ABBV to Buy with a $234 PT. Risk: Humira erosion and pipeline execution against Lilly/Novo in obesity.
May 14AbbVie shares rose 3.3% on upbeat 2026 EPS guidance of $14.37-$14.57 reaffirmed at May 8 AGM; tiny biotech beat AbbVie's $17B Skyrizi in head-to-head trial, raising long-term competition riskMixed▶
AbbVie shares climbed 3.3% on optimism around its raised 2026 EPS guidance of $14.37-$14.57 and strong shareholder approval at its May 8 annual meeting, where all directors were re-elected and Ernst & Young was ratified as auditor. Q1 results showed $15B in revenue (above $14.7B guidance), up 12.4% YoY, driven by Skyrizi +29% and Rinvoq +20%. However, on May 11 a tiny biotech reported clinical data beating AbbVie's $17B Skyrizi franchise in a head-to-head trial, raising medium-term competition concerns. AbbVie also presented at the BofA Healthcare Conference on May 13 and completed an early safety study for pipeline asset ABBV-142. Risk: Skyrizi is the key growth pillar post-Humira biosimilars; any meaningful share loss to next-gen competitors could compress the bull case.
May 13AbbVie participates in BofA Healthcare Conference May 13 with raised 2026 guidance of $67.3B revenue (+10%) and EPS of $14.08-$14.28.Positive▶
AbbVie participates in the Bank of America Securities Healthcare Conference on May 13, 2026. The company recently raised full-year 2026 guidance to $67.3B revenue (10% growth) and adjusted EPS of $14.08-$14.28 (40-42% growth) on the back of strong Q1 results, where net revenues hit $15.0B (+12.4% YoY). Immunology drugs were the key engines: Skyrizi generated $4.48B (+30.9% YoY) and Rinvoq also posted ~20% growth. AbbVie has approximately 90 treatments in development, with 60 in mid- or late-stage. Potential overhang: clinical-stage biotech Oruka Therapeutics (ORKA) reported encouraging data that raises competitive concerns for Skyrizi over time.
May 12AbbVie raised 2026 adjusted EPS guidance to $14.08-$14.28 after Q1 revenue grew 12.4% YoY to $15.0B, driven by Skyrizi's 30.9% jump to $4.48B; BofA upgraded to Buy with $234 PT.Positive▶
AbbVie reported Q1 2026 net revenues of $15.0 billion, up 12.4% YoY, and raised full-year adjusted diluted EPS guidance to $14.08-$14.28 (from $13.96-$14.16). Immunology growth was the highlight: Skyrizi revenues hit $4.48 billion (+30.9% YoY) and Rinvoq grew ~20% on label expansions. BofA's Tim Anderson upgraded ABBV to Buy from Neutral with a PT of $234 (raised from $226). The company announced a $1.4 billion manufacturing campus in Durham, NC on May 6, hiring 734 employees by 2028 to support immunology, neuroscience, and oncology production. Long-term Skyrizi/Rinvoq data was presented at Digestive Disease Week May 2-5 in Chicago, and AbbVie will present at the BofA Healthcare Conference May 13. Consensus is Buy, target ~$256.
May 11AbbVie commits $1.4B to new Durham NC manufacturing campus and presents 18 IBD abstracts at DDW 2026 after raising FY26 guidancePositive▶
AbbVie announced on May 6 a $1.4B investment in a new 185-acre large-scale manufacturing campus in Durham, North Carolina, to produce immunology, neuroscience and oncology medicines, with 734 hires expected over four years and completion by end-2028. At Digestive Disease Week (May 2-5 Chicago), AbbVie presented 18 abstracts including long-term real-world data for SKYRIZI and RINVOQ in Crohn's and ulcerative colitis, and submitted SKYRIZI subcutaneous induction in moderately-to-severely active Crohn's to the FDA. Q1 2026 results delivered 12% revenue growth and 8% adjusted EPS growth, with FY guidance raised to $67.3B revenue (10% growth) and adjusted EPS of $14.08-$14.28 (40-42% growth). AbbVie also bid a $100M upfront challenge to Amgen for a trispecific lung cancer drug. ABBV will present at the BofA Healthcare Conference on May 13. Shares trade ~$201; analyst consensus Buy.
May 8AbbVie Q1 2026 revenue beats at $15B with immunology growth of 16.4%; announces $1.4B North Carolina manufacturing campus creating 734 jobs.Positive▶
AbbVie announced robust first quarter 2026 results with revenue of $15 billion, up 12.4% year-over-year and beating the projected $14.7 billion. Immunology portfolio revenues reached $7.290 billion, up 16.4% on a reported basis. The company revealed a major $1.4 billion manufacturing campus investment in Durham, North Carolina, its largest single-location investment creating 734 jobs, enhancing U.S. pharmaceutical production. AbbVie raised full-year 2026 guidance for revenue and earnings. FDA applications were submitted for upadacitinib for severe alopecia areata and risankizumab for Crohn's disease. Stock jumped over 3% post-earnings with 12-month price target of $254.82, representing 24.28% upside. Management raised guidance and growth driven by Skyrizi and Rinvoq performance.
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| ABBVABBVIE | $221.50 | -0.44% | +3.5% | 13.6x | 0.31 | $390.9B |
| AMGNAMGEN | $341.45 | -1.84% | +3.3% | 14.6x | 0.42 | $184.4B |
| GILDGILEAD | $125.32 | -1.50% | -3.9% | 13.0x | 0.33 | $155.8B |
| VRTXVERTEX | $458.94 | +1.27% | +5.7% | 21.4x | 0.31 | $116.5B |
| REGNREGENERON | $607.24 | -1.22% | -3.5% | 11.3x | 0.24 | $63.7B |
| BIIBBIOGEN | $199.05 | +1.76% | +4.3% | 11.9x | 0.18 | $29.3B |
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price above both MAs — bullish structure.